We are live on ! Find out more
PVCT

PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT

Delisted

PVCT was delisted on the 13th of October, 2016.

Back to rankings

Fund managers haven’t disclosed any holdings of PVCT yet.

PVCT Hedge Fund Activity: Q1 2026 in Review

6 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q1 2026, worth a combined $10.4K — up 1.4% from $10.2K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new PVCT positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Atlas Wealth, opening a new position worth an estimated $999.

  • 6 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q1 2026, up from 5 in Q4 2025.
  • Funds reported $10.4K of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q1 2026, up 1.4% quarter-over-quarter.
  • 1 fund opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q1 2026 and 0 closed out, a net change of +1 holder.
  • The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) buyer in Q1 2026 was Atlas Wealth, an estimated $999 added.

Based on aggregated 13F filings for Q1 2026.